Dr. Jieyi Wang is the founder, Chairman and CEO of Lyvgen Biopharma. He earned his Ph.D. degree from Stony Brook University in New York after graduated from Shanghai Medical University (now Fudan University Shanghai Medical School). Prior to founding Lyvgen in 2016, Dr. Wang worked at Abbott/ AbbVie for 22 years in Oncology R&D and led research teams to deliver various antibody protein drugs into clinical development, including monoclonal antibody, bi-specific antibody and antibody drug conjugate (ADC) Teliso-V designated as breakthrough therapy by FDA. His recent work focuses on tumor immunology and Immuno-Oncology (IO) Discovery, contributing to the better understanding of tumor immuno-infiltration, tumor immunity and structure and function of IO therapeutic antibodies including new generation of multifunctional agonistic antibodies LVGN6051(4-1BB/CD137) and LVGN7409(CD40) in phase 2 clinical development in the US and China. Dr. Wang is author of 50 manuscripts and 30 patent publications.